ADOPT sub-biobank21 September 2021
In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT.
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.
Assessment of research with material from an existing biobank.28 January 2021
If you want to perform research with material from a biobank and the initiation of this biobank has already been approved by the CMO Radboudumc, you only need to submit an application to the CMO Radboudumc for assessment in certain cases.
Financial regulation for sub-biobanks15 September 2020
Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.
Opt-out versus Opt-In Consent for Residual Samples17 October 2019
The Radboud Biobank will be conducting a 6-month feasibility study, as proposed by the Netherlands Federation of University Medical Centers (NFU), to evaluate the impact of migrating to a opt-in method, which requires explicit consent from the patient for use of the residual material.